Clinics and Practice (Jan 2022)
Establishment of the First Comprehensive Adult and Pediatric Hematopoietic Stem Cell Transplant Unit in the United Arab Emirates: Rising to the Challenge
- Humaid O. Al-Shamsi,
- Amin Abyad,
- Panayotis Kaloyannidis,
- Amro El-Saddik,
- Ahmad Alrustamani,
- Ibrahim Abu Gheida,
- Azzam Ziade,
- Norbert W. Dreier,
- Urfan Ul-Haq,
- Thanda Lucy Ann Joshua,
- Abdul Rahman El Kinge,
- Ritika Coelho,
- Dima Ibrahim,
- Mehdi Afrit,
- Bilal Al-Lababidi,
- Zainul Aabideen,
- Mayur Sabhani,
- Rakeshkumar Shah,
- Ghaith Makhlouf,
- Lana Iskandaerani,
- Faryal Iqbal,
- Shiny Narayanan,
- Mohammed Ameen,
- Theresa Morrison,
- Charbel Khalil,
- Kayane Mheidly
Affiliations
- Humaid O. Al-Shamsi
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Amin Abyad
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Panayotis Kaloyannidis
- Adult Hematology and SCT Department, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
- Amro El-Saddik
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Ahmad Alrustamani
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Ibrahim Abu Gheida
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Azzam Ziade
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Norbert W. Dreier
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Urfan Ul-Haq
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Thanda Lucy Ann Joshua
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Abdul Rahman El Kinge
- NMC Royal Hospital, Sharjah, United Arab Emirates
- Ritika Coelho
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Dima Ibrahim
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Mehdi Afrit
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Bilal Al-Lababidi
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Zainul Aabideen
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Mayur Sabhani
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Rakeshkumar Shah
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Ghaith Makhlouf
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Lana Iskandaerani
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Faryal Iqbal
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Shiny Narayanan
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Mohammed Ameen
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Theresa Morrison
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Charbel Khalil
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- Kayane Mheidly
- Department of Oncology and Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- DOI
- https://doi.org/10.3390/clinpract12010010
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 84 – 90
Abstract
Hematopoietic stem cell transplantation (HSCT) is increasingly indicated for various malignant and non-malignant diseases. In the United Arab Emirates (UAE), patients that could benefit from the procedure commonly need to seek medical care abroad in view of the lack of a comprehensive HSCT facility that could offer the full spectrum of interventions and monitoring protocols. This comes with considerable challenges related to coverage and logistics of travel. It also limits the continuity of clinical care, and presents inconvenience to patients who come from a different cultural background. In this article, we share our experiences and lessons learned during the establishment of the first comprehensive adult and pediatric HSCT unit in the UAE that is designed to cater for local citizens and residents, as well as neighboring countries facing similar availability challenges.
Keywords